Table 2:
TNFSF11 (RANKL)1 rs7984870 SNP: Association with Improvement in Study Endpoints for Patients on Testosterone.
| Event | Genotype (N) | N Events (% Between Allele Groups) | Odds Ratio (95% CI) | Fisher’s Exact Pvalue |
|---|---|---|---|---|
| Any Hot Flash Frequency Reduction From Baseline to Week 8 | CC (14) GC+GG (78) |
4 (9.1) 40 (90.9) |
3.53 (0.88–14.12) Reference2 |
0.08 |
| Any Hot Flash Frequency Reduction From Baseline to Week 8 | CC (16) GC+GG (80) |
4 (8.7) 42 (91.3) |
4.32 (1.12–16.70) Reference |
0.044
|
| Any Hot Flash Score Reduction From Baseline to Week 8 | CC (16) GC+GG (80) |
5 (10.2) 44 (89.8) |
3.52 (0.94–13.22) Reference3 |
0.07 |
| Any Joint Pain Reduction From Baseline to Month 3 | CC (16) GC+GG (80) |
7 (12.3) 50 (87.7) |
2.86 (0.83–9.81) Reference3 |
0.10 |
A total of 104 patients were treated with testosterone and 8 of them did not have any genetic information.
1
TNFSF11( RANKL): oesteoprotegerin ligand and a member of the tumor necrosis factor (TNF) superfamily 11.
2
Caucasian samples alone
3
All patients on testosterone
4
association reaching statistical significance, p<,0.05